DAA治疗前EOB-MRI非富血供低信号结节预测HCV感染SVR后肝癌发生
本研究纳入383例接受直接抗病毒药物(DAA)治疗并获得持续病毒学应答(SVR)的HCV感染患者,用钆塞酸二钠增强MRI(EOB-MRI)于治疗前检测非富血供低信号结节(NHHN)。32例(8.4%)存在NHHN,其SVR后新发肝癌发生率显著高于无NHHN者(1、3、5年分别为9.8%、24.2%、41.6% vs 0%、1.2%、4.4%,P<0.0001)。NHHN presence和肝硬化是独立危险因素。
要点
- DAA前EOB-MRI检出NHHN者SVR后5年新发肝癌率达41.6%,显著高于无NHHN者的4.4%。
- NHHN(调整HR 10.86)和肝硬化(调整HR 7.23)是新发肝癌的独立危险因素。
- 对DAA前EOB-MRI存在NHHN的HCV患者,SVR后仍需加强肝癌监测。
核心结论
- DAA治疗前EOB-MRI检出NHHN是HCV感染患者获得SVR后新发肝癌的强危险因素。
研究设计与样本
- 回顾性队列研究,纳入383例接受DAA治疗并获得SVR的HCV感染患者,治疗前均行EOB-MRI检查NHHN。
主要发现
- 32例(8.4%)患者在DAA治疗前检出NHHN。
- NHHN组与无NHHN组SVR后1、3、5年新发肝癌累积发生率分别为9.8%、24.2%、41.6% vs 0%、1.2%、4.4%(P<0.0001)。
- DAA前存在NHHN(调整HR 10.86;95%CI 4.03-31.64)和肝硬化(调整HR 7.23;95%CI 1.88-35.85)与SVR后肝癌发生独立相关。
- 经年龄、性别、规律饮酒、糖尿病、肝硬化、FIB-4指数和血清甲胎蛋白调整及逆概率治疗加权后,NHHN组肝癌发生率仍更高。
临床怎么用
- 对计划接受DAA治疗的HCV患者,治疗前可考虑行EOB-MRI评估NHHN以分层肝癌风险。
- 存在NHHN的患者即使获得SVR,仍应纳入强化肝癌监测方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of risk factors for the development of hepatocellular carcinoma (HCC) after a sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection is urgently needed for HCC surveillance. AIMS: To evaluate whether the presence of non-hypervascular hypointense nodules (NHHNs) depicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) before direct-acting antivirals (DAAs) therapy is a risk factor for de novo HCC development after SVR. METHODS: The presence of NHHNs was examined with EOB-MRI before the start of DAA therapy in 383 patients with HCV infection who achieved SVR. The incidence of de novo HCC after SVR was compared between patients with versus without NHHNs. RESULTS: NHHNs were detected before DAA therapy in 32 patients (8.4%). The incidence of de novo HCC after SVR was significantly higher in patients with NHHNs than in those without (1-, 3-, 5-year incidence, 9.8%, 24.2% and 41.6% vs. 0%, 1.2% and 4.4%, P < 0.0001). The presence of NHHNs before DAA therapy (adjusted HR, 10.86; 95% CI, 4.03-31.64) and cirrhosis (adjusted HR, 7.23; 95% CI, 1.88-35.85) were independently associated with a higher incidence of HCC after SVR. A higher incidence of de novo HCC after SVR remained after adjustment for age, gender, regular alcohol intake, diabetes, cirrhosis, FIB-4 index and serum alpha-foetoprotein with inverse probability of treatment weighting. CONCLUSIONS: This study confirmed that the presence of NHHNs before DAA therapy is a strong risk factor for the development of de novo HCC after SVR.
引用
- Toyoda H, Yasuda S, Shiota S, et al. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection. Aliment Pharmacol Ther. 2021. PMID: 33896023. doi:10.1111/apt.16382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。